SCHEMBL6326985

SCHEMBL6326985

Cc1cc(C(=O)O)[nH]c1/C=C1\C(=O)Nc2cccc(-c3ccc(Br)cc3)c21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 11/20 0.51
RET P07949 5/20 0.47
FGFR1 P11362 5/20 0.47
PDGFRB P09619 5/20 0.47
ALK Q9UM73 3/20 0.47
FLT1 P17948 3/20 0.47
CSF1R P07333 2/20 0.47
SRC P12931 2/20 0.47
FGFR3 P22607 2/20 0.47
MAPK1 P28482 2/20 0.47
FLT4 P35916 2/20 0.47
FLT3 P36888 2/20 0.47
PDPK1 O15530 2/20 0.47
MEN1 O00255 1/20 0.47
NPC1 O15118 1/20 0.47
GMNN O75496 1/20 0.47
USP2 O75604 1/20 0.47
ABL1 P00519 1/20 0.47
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6326989 1.00 KDR (0.51) KDRRETFGFR1PDGFRBALK
SCHEMBL6322309 0.91 KDR (0.50) KDRRETFGFR1PDGFRBALK
SCHEMBL6321545 0.91 KDR (0.50) KDRRETFGFR1PDGFRBALK
SCHEMBL6321187 0.90 KDR (0.51) KDRRETFGFR1PDGFRBALK
SCHEMBL6319577 0.90 KDR (0.51) KDRRETFGFR1PDGFRBALK
SCHEMBL6321190 0.90 KDR (0.51) KDRRETFGFR1PDGFRBALK
SCHEMBL6319589 0.90 KDR (0.51) KDRRETFGFR1PDGFRBALK
SCHEMBL6321073 0.88 KDR (0.52) KDRRETFGFR1PDGFRBALK
SCHEMBL6321070 0.88 KDR (0.52) KDRRETFGFR1PDGFRBALK
SCHEMBL5830130 0.88 KDR (0.51) KDRRETFGFR1PDGFRBALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US claimed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP claimed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US claimed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO claimed
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 KDR 819/4885RET 658/4885FGFR1 525/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 KDR 819/4885RET 658/4885FGFR1 525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.